Compare Snap On Incorporated (SNA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snap On Incorporated vs State Street SPDR S&P Biotech ETF — how do they compare? Snap On Incorporated trades at $408.11 (market cap $21.30B), while State Street SPDR S&P Biotech ETF trades at $159.21. The key difference: Snap On Incorporated pays a 2.37% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| SNA | XBI | |
|---|---|---|
Market Cap | $21.30B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $419.31 | $164.28 |
52-Week Low | $321.38 | $86.92 |
Enterprise Value | $20.93B | — |
Dividend Yield | 2.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snap-on Incorporated (SNA) trades at $408.44, down 0.65% with a bullish technical outlook supported by moving averages. The company maintains strong fundamentals with 19.6% net income margin and 17.58% ROE, though valuation metrics appear elevated. Recent Q2 2026 earnings beat expectations with $4.96 EPS, while the $100 million Diesel Laptops acquisition expands diagnostics capabilities.
SNA offers steady growth potential with strong cash flow generation and consistent dividends, but faces integration risks from recent acquisitions and premium valuation concerns. Analyst consensus remains bullish with $455.33 price target, though execution on growth initiatives will be critical for sustaining momentum amid competitive pressures.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
